Clinical features, diagnosis and therapy of familial haemophagocytic lymphohistiocytosis

Acta Paediatr. 2021 Oct;110(10):2723-2728. doi: 10.1111/apa.15889. Epub 2021 May 19.

Abstract

Familial haemophagocytic lymphohistiocytosis (FHL) is an inherited immune deficiency with defective cytotoxicity of natural killer cells and cytotoxic T lymphocytes. A highly stimulated, but ineffective immune response leads to severe hyperinflammation. Clinical and laboratory features are characteristic, but unspecific; thus awareness of FHL is important for early diagnosis. FHL is rapidly fatal without treatment. Standard-of-care therapy is etoposide and corticosteroids, followed by haematopoietic stem cell transplantation (HSCT). CONCLUSION: FHL has become a curable disease with present treatment. Additional cytokine-directed therapy still has to prove its value. Earlier HSCT and less toxic conditioning regimens will lead to improved cure rates.

Keywords: cytokines; haematopoietic stem cell transplantation; haemophagocytic lymphohistiocytosis; immune deficiency; lymphocyte cytotoxicity.

Publication types

  • Review

MeSH terms

  • Cytokines
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Lymphohistiocytosis, Hemophagocytic* / diagnosis
  • Lymphohistiocytosis, Hemophagocytic* / genetics
  • Lymphohistiocytosis, Hemophagocytic* / therapy

Substances

  • Cytokines